Biocon Q4 Results: Cons PAT grows 31% YoY to Rs 313 crore, revenue surges 57%

May 23, 2023

The board has recommended a final dividend payout of Rs 1.50 per share. In FY23, Biocon’s revenue grew almost 37% to Rs 11,174 crore, while its net profit fell nearly 29% to Rs 463 crore. The biosimilars business segment more than doubled its year-on-year revenue to INR2,102 crore in Q4 2022.

More To Explore

MF Tracker: Can this top performing smallcap fund keep winning streak alive?

Bandhan Small Cap Fund has delivered impressive returns, outperforming its benchmark and category averages over multiple periods. Fund manager changes and strategic sector allocation contributed

April 7, 2025

Keep cash, keep calm, and carry on: Radhika Gupta of Edelweiss Mutual Fund advises during market turmoil

The CEO posted on social media, “This day. 5 years ago. When everything was red and the world looked like it would end. Keep cash

April 7, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003